Esperion Therapeutics Soars into 2026 with Momentum and a Clear Vision for the Future
Esperion Therapeutics, a leading player in the cardiometabolic disease space, has just concluded its Q4 2025 earnings conference call, and the news is nothing short of exciting. The company, led by President and CEO Sheldon Koenig, has reported a defining and transformative year that sets it up for continued success in 2026.
2025 was marked by strong commercial execution, a fortified financial foundation, and a renewed commitment to putting patients at the heart of everything the company does. As Koenig proudly noted, "We enter 2026 with strong momentum and a clear path forward." This is largely due to the introduction of Vision 2040, the company's long-term ambition and roadmap for achieving it.
A key component of this vision is the planned acquisition of Corstasis Therapeutics. This transformational step will give Esperion two powerful global franchises to grow: its global bempedoic acid portfolio and Enbumyst, a first-in-class intranasal diuretic addressing meaningful needs in heart failure care. This combination aligns with Esperion's existing cardiology footprint, accelerates growth, and offers patients more impactful, patient-friendly options across the continuum of cardiometabolic disease.
The acquisition is also seen as a catalyst for additional long-term value and a testament to Esperion's commitment to building a larger and sustainably profitable company. The priority, according to Koenig, is to grow these two franchises to their multi-billion-dollar potential.
In terms of the progress made on building the U.S. bempedoic acid franchise, Esperion achieved strong prescription growth, broadened payer coverage, and focused sales and marketing efforts on statin-tolerant patients. This allowed the company to drive Q4 year-over-year sales by 38%, increase retail prescription equivalents by 34%, and expand the number of unique healthcare practitioners prescribing NEXLETOL and NEXLIZET by nearly 25%.
Looking ahead, Esperion anticipates continued momentum in 2026, driven by strong reimbursement and favorable positioning in the US dyslipidemia guidelines. The American College of Cardiology's scientific statement on inflammation and cardiovascular disease has formally recognized the link between inflammation measured by hsCRP and ASCVD, providing a call to action for broad screening of hsCRP for primary and secondary prevention patients in combination with LDL cholesterol screening.
The recognition of Esperion's bempedoic acid-based treatments as agents to reduce hsCRP is also significant. As Koenig noted, "NEXLETOL and NEXLIZET are the only non-statins proven to reduce hsCRP by up to 46%." This positions Esperion well for continued growth in the cardiometabolic disease space.
